Skip directly to content

CHAMPIX referenties

  • 1. Samenvatting van de productkenmerken van CHAMPIX®. Zie www.pfizer.nl voor meest recente versie.
  • 2. Aubin H-J et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial. Thorax 2008; 63:717–724.
  • 3. Patiëntenbijsluiter van CHAMPIX®. Juli 2016.
  • 4. Hughes JR. New treatments for smoking cessation. CA Cancer J Clin 2000; 50:143-151.
  • 5. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). Cochrane Database Syst Rev. 2013 May 31;5:CD009329. doi: 10.1002/14651858.CD009329.pub2.
  • 6. Nides M et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32:664–675.
  • 7. Rennard S et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012; 14:343–350.
  • 8. McEwen A et al. Manual of smoking cessation. A guide for counsellors and practitioners. 2006, Addiction Press: Blackwell Publishing.
  • 9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Vierde editie, tekstherziening. Washington, DC: American Psychiatric Association; 2000.
  • 10. Rigotti NA et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A randomised trial. Circulation 2010; 121:221–229.
  • 11. Tonstad S et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33:289–301.
  • 12. Gonzales D et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006; 296:47–55.
  • 13. Jorenby DE et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. JAMA 2006; 296:56–63.
  • 14. Cappelleri JC et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007; 32:912–923.
  • 15. Andreas S et al. Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study. Eur Addict Res 2013; 19:47–54.
  • 16. Boudrez H et al. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011; 27(4):769–775.
  • 17. West R, Shiffman S. Fast Facts. Smoking cessation. Indispensable guides to clinical practice. 2004, Oxford: Health Press.
  • 18. European Public Assessment Report (EPAR). CHAMPIX: Scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000699/WC500025254.pdf. Laatst bekeken: 17 juni 2016.
  • 19. Coe JW et al. Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474–3477.
  • 20. West R et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008; 197:371–377.
  • 21. Jarvis MJ. Why people smoke. BMJ 2004; 328:277–279.
  • 22. Tonstad S et al. Effect of maintenance therapy with vareniciline on smoking cessation. A randomized controlled trial. JAMA 2006; 296:64–71.
  • 23.Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009; 104:719–33.
  • 24.Anthenelli RM, Morris C, Ramey TS et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression. A randomised trial. Ann Intem Med 2013;159:390–400.
  • 25.Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events Am J Psychiatry 2013;170: 1460–1467.